News | BioNTech

10 March 2026

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

10 March 2026

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Read on

24 February 2026

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Read on

28 January 2026

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Read on

21 January 2026

BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16+ Head and Neck Cancer

Read on

12 January 2026

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Read on

12 January 2026

BioNTech and OncoC4 Receive FDA Orphan Drug Designation for Gotistobart in Squamous Non-Small Cell Lung Cancer

Read on

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.